Introduction to Pd L1 Positive
Sentence Examples
Discover more insights into Pd L1 Positive
Keywords frequently search together with Pd L1 Positive
Narrow sentence examples with built-in keyword filters
Pd L1 Positive sentence examples within non small cell
e18731Background: For advanced non-small cell lung cancer (NSCLC), evidence from clinical trials indicates the superiority of pembrolizumab (P) than chemotherapy (C) in PD-L1 positive patients and.
Full Text
Analysis of metastasis-negative lymph nodes of non-small-cell lung cancer patients revealed that macrophage PD-L1 positively correlates with levels of GLUT-1 and vesicle release gene YKT6 from primary tumors.
Full Text
Pd L1 Positive sentence examples within progression free survival
Overall and progression-free survival between PD-L1 positive and PD-L1 negative patients were not different across all histological types, and each subtype in particular for serous carcinomas expressing PD-L1.
Full Text
IMpassion130 was the first clinical trial to indicate that combining anti-PD-L1 with standard-of-care chemotherapy (nab-paclitaxel) to treat TNBC increases progression-free survival in patients exclusively those with PD-L1 positive tumors.
Full Text
Pd L1 Positive sentence examples within triple negative breast
PD-L1 positive and TOP3A mutation were significantly associated with early triple-negative breast cancer prognosis.
Full Text
BACKGROUND
Programmed-cell-death-ligand 1 (PD-L1) inhibitor treatment is approved for metastatic/recurrent, PD-L1 positive, triple-negative breast cancer (TNBC) and solid tumors with mismatch repair (MMR) defect regardless of PD-L1 status.
Full Text
In our case, we firstly reported a rare spinal CCM patient with PD-L1 positive and multiple metastases benefiting from PD-1 inhibitor plus anti- angiogenesis therapy.
Full Text
Conclusion: This case described here demonstrated that immunotherapy of PD-1 inhibitor is a promising treatment option for refractory MFS with PD-L1 positive or tumor mutational burden -high, which could contribute to effective tumor response.
Full Text
In addition, the ratio of PD-L1 positive expression (≥1%) in mutation group (48.
Full Text
Final overall survival (OS) analysis of IMpassion130 confirmed the clinically relevant OS improvement observed with the addition of atezolizumab to first-line nab-paclitaxel in metastatic PD-L1 positive TNBC.
Full Text
Overall and progression-free survival between PD-L1 positive and PD-L1 negative patients were not different across all histological types, and each subtype in particular for serous carcinomas expressing PD-L1.
Full Text
3 times more common among PD-L1 negative than PD-L1 positive ADC; the solid subtype was 1.
Full Text
Molecular Templates has developed MT-6402, an engineered toxin body (ETB) targeting PD-L1, as a single agent immunotoxin designed to overcome the challenges of current PD-L1 targeting approaches by 1) directly depleting PD-L1 positive tumor cells or immunosuppressive immune cells displaying PD-L1 in the tumor microenvironment and 2) delivery of an HLA: A*02 restricted viral peptide to alter the tumor immunophenotype for recruitment of CMV-restricted CTLs to target the tumor for depletion (antigen seeding).
Full Text
PD-L1 overexpression was rare, both in primary tumors and brain metastases, but PD-L1 positive primary tumors were associated with worse OS (p=0.
Full Text
No significant differences in the 3-EFS and OS rates were observed between the PD-1/PD-L1 positive and negative groups.
Full Text
The pCR rate also increased both in PD-L1 positive (OR: 1.
Full Text
PD-L1 positive (≥ 1%) subgroup showed a median PFS of 6.
Full Text
However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies.
Full Text
After just four rounds, high-affinity aptamers for PD-L1 positive sEVs were selected as novel affinity reagents.
Full Text
Immunotherapy treatment in HNSCC demonstrates a discreet but still significant improvement in the overall survival of PD-L1 positive subjects.
Full Text
Pembrolizumab was recommended for the treatment of PD-L1 positive tumors in esophageal cancer and the combined positive score (CPS) was reported to be a better predictor of efficacy compared to the tumor proportion score (TPS).
Full Text
Results The PD-L1 DLS significantly discriminated between PD-L1 positive and negative patients (area under receiver operating characteristics curve ≥0.
Full Text
Overall, levels of CD8+ TILs, PD-1 and PD-L1 positive immune cells increased significantly (p <0.
Full Text
In addition, in Chinese cohort, KMT2C mutation was associated with higher PD-L1 positive expression (≥1%) (P = 0.
Full Text
0% of PD-L1 positive patients and 3.
Full Text
92%), while co-mutations patterns were characteristic in type I, and the PD-L1 positive subgroup showed higher carbohydrates, lipids, and xenobiotics metabolism compared to others.
Full Text
Based on the analysis of the H-Score, no significant difference was noted regarding disease-free survival time between PD-L1 positive and PD-L1 negative patients (median 20 [95% CI 1.
Full Text
Tumor cells were divided into two populations by CD326 expression levels, and the PD-L1 positive ratios were inversely correlated with the rate of CD326 highly expressing cells as well as mean fluorescein intensity of CD326 in tumor cells, while positively correlated with the frequencies of stromal cells or myeloid cells in CRC.
Full Text
Among the 125 patients, 89 were classified as having PD-L1 positive expression.
Full Text
At a cut-off level of 5% PD-L1 positive tumor cells, PD-L1 positivity was seen in 6.
Full Text
Only 2 cases were PD-L1 positive on tumor cells and none PD-1 positive.
Full Text
After stratification for PD-L1 expression, OS, PFS, and ORR of PD-L1 positive patients were significantly increased in the experimental group (HR 0.
Full Text
Immune checkpoint inhibitor (ICI) treatment is an integral part of second line treatment of patients with urothelial carcinoma (UC) as well as in first line in cisplatin-ineligible patients with PD-L1 positive tumours.
Full Text
Patients were divided into 3 groups: no CTC detectable (CTCnull, n = 15), PD-L1 positive CTC (CTCpos, n = 13), and PD-L1 negative CTC (CTCneg, n = 11).
Full Text
Anti-PD-1 therapy significantly prolonged the OS when compared with chemotherapy, while no significantly difference in PFS and ORR for the population of esophageal cancer, ESCC， PD-L1 positive.
Full Text
6% patients had PD-L1 positive expression (TPS≥1%), but showed no association with recurrence.
Full Text
Conclusions: Only a small proportion of LMS are TMB-H or MSI-H, suggesting that the neoantigen burden in LMS may be insufficient to promote a robust anti-tumor response, even in the presence of PD-L1 positive tumor cells.
Full Text
Y111 induced the activation of the expanded Vγ2Vδ2 T cells in a dose-dependent fashion in the presence of PD-L1 positive tumor cells.
Full Text
RESULTS
PD-L1 positive tumor cells (TCs-PDL1) were observed in 96% of patients and PD-L1 positive immune cells (ICs-PDL1) were observed in 90.
Full Text
The worst prognosis was observed in patients with T-cadherin negative/PD-L1 positive.
Full Text
5%) were found PD-L1 positive, which is comparable to other types of tumor.
Full Text
89Zr-REGN3504 immuno-PET accurately detected a significant reduction in splenic PD-L1 positive cells following systemic treatment with clodronate liposomes.
Full Text
PD-L1 positive and TOP3A mutation were significantly associated with early triple-negative breast cancer prognosis.
Full Text
More PD-L1 positive patients responded to avelumab monotherapy compared to PD-L1 negative patients.
Full Text
Both patients had PD-L1 positive vaginal tumors and tolerated treatment well.
Full Text
For PD-L1 positive pts the ORR was 15.
Full Text
In total, 81 patients were enrolled (HNSCC: N = 41 [PD-L1 positive: n = 19]; NSCLC: N = 40 [PD-L1 positive: n = 16]); median treatment duration was 72 days (range, 1–617) and 71 days (range, 1–490) for the HNSCC and NSCLC cohorts, respectively.
Full Text
The percentage of PD-L1 positive tumor cells in relation to the total number of tumor cells was determined.
Full Text
Out of 13 PD-L1 positive tumors, 38.
Full Text
However, after radiotherapy and chemotherapy, PD-L1 positive expression was found in a re-biopsy specimen, and NGS detection indicated the loss of immune negative predictive genes.
Full Text
The analysis assessed only the direct medical cost (tissue biopsy, PD-L1 assay, specialist visit, pharmacological treatment with atezolizumab in combination with nab-paclitaxel) of patients with PD-L1 positive mTNBC, and management of the adverse events associated with the pharmacological treatment administered.
Full Text
The number of intratumoral CD8+ lymphocytes was strikingly higher in PD-L1 positive (939.
Full Text
Of these 9 patients, 3 had PD-L1 positive (>20%) on tumor cells and 6 had PD-L1 negative (range 0–10%) on tumor cells.
Full Text
The
experimental groups had longer OS than the control groups in patients
with PD-L1 positive (OR = 0.
Full Text
SCLC patients with low LOH had numerically higher PD-L1 positive expression than those with high LOH (20.
Full Text
BACKGROUND
Programmed-cell-death-ligand 1 (PD-L1) inhibitor treatment is approved for metastatic/recurrent, PD-L1 positive, triple-negative breast cancer (TNBC) and solid tumors with mismatch repair (MMR) defect regardless of PD-L1 status.
Full Text
Two residual-convolutional-network (ResCNN) models to predict EGFR mutation and PD-L1 positive status were trained (N=429) and validated (N=187) with PET/CT images and clinical data of 616 patients from SPH and HBMU, and then tested using external HMU test cohort with EGFR mutation status (N=65) and HLM test cohort with PD-L1 expression status (N=85).
Full Text
e18731Background: For advanced non-small cell lung cancer (NSCLC), evidence from clinical trials indicates the superiority of pembrolizumab (P) than chemotherapy (C) in PD-L1 positive patients and.
Full Text
In conclusion, our work provides an in vitro proof-of-concept of PCI-enhanced targeting and eradication of PD-L1 positive immunosuppressive cells.
Full Text
Conclusion: According to IASLC/ATS/ERS lung adenocarcinoma classification, the predominant-solid pattern is associated with a higher proportion of PD-L1 positive samples, no subtype was identified to be associated with a high (≥50%) TPS PD-L1.
Full Text
The prevalence of PD-L1 positive, TMB-H, MSI-, and HLA-I -heterozygous was 47.
Full Text
Twenty-eight patients were PD-L1 positive in MVs at baseline, of which 18 were in the GEMnPAC cohort and 10 in the FOLFIRINOX one.
Full Text
In the biomarker analysis, all patients were MMR-proficient status; 14 patients were evaluated for PD-L1 expression compared with PD-L1 negative cases (n = 5), PD-L1 positive cases (n = 9) did not show higher RR or longer PFS, responses were observed in both groups.
Full Text
Median PFS2 was compared between groups stratified by a cutoff median PFS1 of 3m, sequence of PD-1 and PD-L1 inhibitors, and PD-L1 positive and negative subsets.
Full Text
The benefit was significant in the PD-L1 positive subgroup (SOR = 1.
Full Text
Conclusions For treatment-naive PD-L1 positive MSTS, NPI seems to be less tolerated but has a greater survival advantage than NIV as the primary therapy.
Full Text
This is evidenced by study results that in the neoadjuvant settings PD-(L)1 inhibitors have efficacy in both PD-L1 positive and negative populations, whereas in the advanced setting, efficacy has only been reported in PD-L1 positive patients.
Full Text
Analysis of metastasis-negative lymph nodes of non-small-cell lung cancer patients revealed that macrophage PD-L1 positively correlates with levels of GLUT-1 and vesicle release gene YKT6 from primary tumors.
Full Text
Exon 19 deletion was more prevalent in PD-L1 negative tumors whereas exon 21 substitution (L858R) was seen more in PD-L1 positive tumors.
Full Text
In comparison with other groups, G1 was significantly associated with classical morphology, invasive growth, lymphatic invasion (LI), vascular invasion (VI), psammoma bodies, intratumoral fibrosis, PD-L1 positive tumour-infiltrating lymphocytes, and multinuclear giant cells (MGCs).
Full Text
PD-L1 positive (CPS≥5) rates were similar in CDKN2A/B loss, MDM2/4 amp and wild-type groups in the whole cohort (26.
Full Text
The prominent infiltration of PD-L1 positive cells was observed in the upper dermis of pembrolizumab-induced BP.
Full Text